IJGC Podcast

Prophylactic Negative Pressure Wound Therapy RCT with Mario Leitao

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mario Leitao to discuss prophylactic negative pressure wound therapy RCT. Dr. Leitao is currently an Attending Surgeon in the Department of Surgery at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Obstetrics and Gynecology at Weill Cornell Medical College. He currently serves as Program Director for the Gynecologic Oncology Fellowship. Dr. Leitao is also the Director for the Minimal Access and Robotic Surgery Program in the Department of Surgery for MSKCC. Dr. Mario Leitao is currently an Attending Surgeon in the Department of Surgery at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Obstetrics and Gynecology at Weill Cornell Medical College. He currently serves as Program Director for the Gynecologic Oncology Fellowship. Dr. Leitao is also the Director for the Minimal Access and Robotic Surgery Program in the Department of Surgery for MSKCC.
Highlights
1. SSI is a common postoperative complication that leads to significant healthcare costs in the near- and far-term
2. In our RCT, the use of a negative pressure wound therapy (NPWT) system did not improve wound complications (Superficial SSI) in a cohort of patients undergoing mostly laparotomy for gynecologic malignancies with closed laparotomy incisions.
3. There was also no signal of benefit in the small subgroup of morbidly obese patients.
4. Increasing BMI was the only independently associated risk for the development of a wound complication
@leitaomd @sloan_kettering

Reviewing the November Issue with Sara Nasser (Arabic Version)

In this episode of the IJGC Podcast, Editorial Fellow Sara Nasser discusses the contents of the November issue of IJGC in Arabic.

Reviewing the November Issue with Cecilia Darin and Natalia Rodriguez (Spanish version)

In this episode of the IJGC Podcast, Editorial Fellows Cecilia Darin and Natalia Rodriguez discuss the contents of the November issue of IJGC in Spanish.

Reviewing the November Issue with Emma Allanson and Natalia Rodriguez (English version)

In this episode of the IJGC Podcast, Editorial Fellows Emma Allanson and Natalia Rodriguez discuss the contents of the November issue of IJGC in English.

GROINSS-V-II/GOG 270 Trial with Ate van der Zee and Brian Slomovitz

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Ate van der Zee and Brian Slomovitz to discuss the GROINSS-V-II/GOG 270 Trial. Dr. Brian Slomovitz is a Gynecologic Oncologist at Broward Health and Professor of Obstetrics and Gynecology at the Wertheim College of Medicine at Florida International University. He is an internationally recognized leader in gynecologic oncology clinical trials, specifically in immunotherapy and novel biomarker therapeutics. He also is a leader in sentinel lymph node detection for gynecologic malignancies. Dr. Ate Van der Zee is Chairman of the Board of Directors at the University Medical Center Groningen and professor of Gynaecological Oncology. His current research focuses on translational and clinical research in vulvar cancer. Together with Dr. Oonk he leads a world-wide consortium (GROINSS-V), which performs landmark clinical studies in vulvar cancer. Dr. van der Zee combines his current position chairman position with clinical work and academic research.
Highlights
•Radiotherapy instead of inguinofemoral lymphadenectomy is a safe treatment option for vulvar cancer patients with a metastasis Ate van der Zee and Brian Slomovitz (@AteZee / @gyncancermd / @umcg / @browardhealth, @FIU)

Racial Inequities in Immunotherapy Trials with Katherine Grette and Nathaniel Jones

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Katherina Grette and Nathaniel Jones to discuss racial inequities in immunotherapy trials and their article, “Not immune to inequity: minority under-representation in immunotherapy trials for breast and gynecologic cancers,” which is the Lead Article in IJGC’s November 2021 issue.
(https://ijgc.bmj.com/content/early/2021/09/21/ijgc-2021-002557)
Dr. Katherine Grette attended medical school at the University of Washington, then completed her residency in Obstetrics and Gynecology at the University of South Alabama prior to joining faculty. She currently practices as a generalist and serves as the Assistant Director of Resident Research for the department.
Dr. Nate Jones completed residency at Mountain Area Health Education Center in Asheville, NC followed by fellowship in Gynecologic Oncology at New York Presbyterian Hospitals: Columbia and Cornell. He currently serves as Assistant Professor in Gynecologic Oncology at the University of South Alabama Mitchell Cancer Institute. His research interests center on targeted cancer therapies, molecular and genomic characteristics of gynecologic malignancies, and addressing racial disparities in gynecologic cancer care.
Highlights
•Minority women are poorly represented in immunotherapy clinical trials for breast and gynecologic cancers
•Enrollment of black women is especially low, accounting for only 5% of participants
•Minority participation in clinical trials must increase to improve equity in health outcomes
@natejones333 / @katgrette / @usamci

Pembrolizumab for Persistent, Recurrent, Metastatic Cervical Cancer:KEYNOTE 826 w/ Nicoletta Colombo

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Professor Nicoletta Colombo to discuss pembrolizumab for persistent, recurrent, metastatic cervical cancer: KEYNOTE 826. Professor Nicoletta Colombo graduated in medicine in 1980, completing specialty training in obstetrics and gynaecology in 1984 at the University of Milan, Italy.
After a training period at Charing Cross Hospital and Royal Marsden Hospital in London, she became a Clinical Research Associate at the Kaplan Cancer Center, New York University, where she worked from 1984 until 1986. Professor Colombo then worked as a member of the Junior and later the Senior Faculty at the Department of Obstetrics and Gynaecology at the University of Milan. In 1994 she became Deputy Director and in 2001 Director of the Medical Gynaecologic Oncology Division, European Institute of Oncology (IEO), Milan, Italy. Since 2002 she has held the position of Associate Professor of Obstetrics and Gynaecology at the University of Milan-Bicocca. In 2008, she became Director of the Ovarian Cancer Centre at IEO and in 2014 Chair of the Program of Gynaecology. Principal investigators of several international clinical trials, Professor Colombo is also author of several publications in the field of gynaecologic oncology, and a member of various professional societies such as the American Society of Clinical Oncology (ASCO), the Society of Gynaecologic Oncologists (SGO) and the International Gynaecological Cancer Society (IGCS). She is also Past President of the European Society of Gynaecologic Oncology (ESGO) and was Chair of the first ESMO-ESGO-ESTRO Consensus Conference in endometrial cancer ( 2015) and the first ESMO-ESGO Consensus Conference in ovarian Cancer ( 2018). From 2016-2020 she was Subject Editor of ESMO Clinical Guidelines for Gynecological Malignancies and she is currently member of the steering committee of ESMO Clinical guidelines.
Highlights
1)adding pembrolizumab to chemotherapy with or without bevacizumab provides statistically significant, clinically meaningful improvements in progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer
2)The addition of pembrolizumab was also associated with a higher response rate and a longer response duration
3)The safety profile for pembrolizumab plus chemotherapy with or without bevacizumab was manageable
4)data from KEYNOTE-826 suggest that pembrolizumab plus platinum-based chemotherapy with or without bevacizumab may be a new first-line standard of care for the treatment of persistent, recurrent, or metastatic cervical cancer.

Reviewing the October Issue with Irina Tsibulak (Russian version)

In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the October issue of IJGC in Russian.

Reviewing the October Issue with Emma Allanson and Natalia Rodríguez(English version)

In this episode of the IJGC Podcast, Editorial Fellows Emma Allanson and Natalia Rodríguez discuss the contents of the September issue of IJGC in English.

JAVELIN 100 & 200 Trials with Bradley Monk

Dr. Bradley Monk is a member of Arizona Oncology and part of the US Oncology Network and continues to practice in Phoenix. Most recently, he has been appointed the US Oncology Medical Director of Gynecologic Oncology Research. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix and works at Arizona Oncology (US Oncology Network).
Dr. Monk’s research interests include the prevention and treatment of gynecologic cancers. Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists) and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncology, International Gynecologic Cancer Society, and American Society of Clinical Oncology. He has authored more than 330 peer-reviewed articles along with more than 30 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.